MX2020009130A - Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. - Google Patents
Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.Info
- Publication number
- MX2020009130A MX2020009130A MX2020009130A MX2020009130A MX2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A
- Authority
- MX
- Mexico
- Prior art keywords
- spla2
- therapeutic anti
- gib
- antibodies
- gib antibodies
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- AIDS & HIV (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos humanos o humanizados que se unen a PLA2-GIB, a su producción y a los usos de los mismos. Estos anticuerpos muestran características ventajosas, en particular, para fines terapéuticos y de diagnóstico..
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305229.9A EP3533460A1 (en) | 2018-03-02 | 2018-03-02 | Therapeutic anti-spla2-gib antibodies and the uses thereof |
| PCT/EP2019/055255 WO2019166665A1 (en) | 2018-03-02 | 2019-03-04 | Therapeutic anti-spla2-gib antibodies and the uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009130A true MX2020009130A (es) | 2021-01-08 |
Family
ID=61691417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009130A MX2020009130A (es) | 2018-03-02 | 2019-03-04 | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210047432A1 (es) |
| EP (2) | EP3533460A1 (es) |
| JP (1) | JP2021515554A (es) |
| KR (1) | KR20200138726A (es) |
| CN (1) | CN112074292A (es) |
| AR (1) | AR114129A1 (es) |
| AU (1) | AU2019226674A1 (es) |
| BR (1) | BR112020017956A2 (es) |
| CA (1) | CA3091992A1 (es) |
| EA (1) | EA202092085A1 (es) |
| IL (1) | IL277007A (es) |
| MX (1) | MX2020009130A (es) |
| SG (1) | SG11202008044PA (es) |
| TW (1) | TW202000230A (es) |
| WO (1) | WO2019166665A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2996464A1 (en) | 2015-08-31 | 2017-03-09 | Diaccurate | Use of indole compounds to stimulate the immune system |
| EP3693063A1 (en) * | 2019-02-06 | 2020-08-12 | Diaccurate | Methods and compositions for treating cancer |
| EP3858357A1 (en) | 2020-01-28 | 2021-08-04 | Diaccurate | Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib |
| WO2021214039A1 (en) | 2020-04-21 | 2021-10-28 | Diaccurate | Spla2hgib-binding molecules and uses thereof |
| WO2021239666A1 (en) | 2020-05-26 | 2021-12-02 | Diaccurate | Therapeutic methods |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| JP2009522234A (ja) * | 2005-12-29 | 2009-06-11 | イミュファルマ・フランス・エスアー | ホスホリパーゼａ２を阻害する組成物および方法 |
| EP2581388A1 (en) * | 2011-10-14 | 2013-04-17 | Centre National de la Recherche Scientifique (CNRS) | Anti-sPLA2-V antibodies and uses thereof |
| US9657109B2 (en) * | 2012-11-02 | 2017-05-23 | Wisconsin Alumni Research Foundation | Compositions and methods for the treatment of systemic inflammatory response syndromes |
| EP2960252A1 (en) * | 2014-06-26 | 2015-12-30 | Institut Pasteur | Phospholipase for treatment of immunosuppression |
-
2018
- 2018-03-02 EP EP18305229.9A patent/EP3533460A1/en not_active Withdrawn
-
2019
- 2019-03-01 AR ARP190100533A patent/AR114129A1/es not_active Application Discontinuation
- 2019-03-04 SG SG11202008044PA patent/SG11202008044PA/en unknown
- 2019-03-04 TW TW108107144A patent/TW202000230A/zh unknown
- 2019-03-04 EP EP19710343.5A patent/EP3758743A1/en not_active Withdrawn
- 2019-03-04 CA CA3091992A patent/CA3091992A1/en active Pending
- 2019-03-04 KR KR1020207026752A patent/KR20200138726A/ko not_active Withdrawn
- 2019-03-04 WO PCT/EP2019/055255 patent/WO2019166665A1/en not_active Ceased
- 2019-03-04 MX MX2020009130A patent/MX2020009130A/es unknown
- 2019-03-04 BR BR112020017956-6A patent/BR112020017956A2/pt not_active IP Right Cessation
- 2019-03-04 EA EA202092085A patent/EA202092085A1/ru unknown
- 2019-03-04 CN CN201980016762.1A patent/CN112074292A/zh active Pending
- 2019-03-04 AU AU2019226674A patent/AU2019226674A1/en not_active Abandoned
- 2019-03-04 US US16/976,486 patent/US20210047432A1/en not_active Abandoned
- 2019-03-04 JP JP2020545806A patent/JP2021515554A/ja active Pending
-
2020
- 2020-08-30 IL IL277007A patent/IL277007A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3533460A1 (en) | 2019-09-04 |
| KR20200138726A (ko) | 2020-12-10 |
| CA3091992A1 (en) | 2019-09-06 |
| BR112020017956A2 (pt) | 2020-12-22 |
| JP2021515554A (ja) | 2021-06-24 |
| SG11202008044PA (en) | 2020-09-29 |
| EA202092085A1 (ru) | 2021-02-09 |
| IL277007A (en) | 2020-10-29 |
| TW202000230A (zh) | 2020-01-01 |
| US20210047432A1 (en) | 2021-02-18 |
| CN112074292A (zh) | 2020-12-11 |
| AU2019226674A1 (en) | 2020-09-17 |
| WO2019166665A1 (en) | 2019-09-06 |
| EP3758743A1 (en) | 2021-01-06 |
| AR114129A1 (es) | 2020-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000089A (es) | Anticuerpos anti-cd3 y usos de estos | |
| MX2021015518A (es) | Anticuerpos que se unen a cd39 y sus usos. | |
| MX393066B (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| CO2019014414A2 (es) | Moléculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| PE20210488A1 (es) | Anticuerpos especificos para gucy2c y sus usos | |
| ECSP18041833A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos | |
| CO2017013356A2 (es) | Anticuerpos de factor xi | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| PE20171041A1 (es) | Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion | |
| CL2019000799A1 (es) | Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433) | |
| CU24427B1 (es) | Moléculas de anticuerpo que se unen a tim-3 | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| UY37030A (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| CO2018004569A2 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| CL2025000292A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| MX2017004196A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos |